CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA

被引：0
|
作者：
Gay, F. [1 ]
Scalabrini, D. Rota [2 ]
Belotti, A. [2 ]
Offidani, M. [2 ]
Tacchetti, P. [2 ]
Petrucci, M. T. [2 ]
Pautasso, C. [1 ]
Palmas, A. D. [2 ]
Siniscalchi, A. [2 ]
Grasso, M. [2 ]
Spadano, A. [2 ]
Giuliani, N. [2 ]
Ballanti, S. [2 ]
Patriarca, F. [2 ]
Canepa, L. [2 ]
Bernardini, A. [1 ]
Aquino, S. [2 ]
Gamberi, B. [2 ]
Zambello, R. [2 ]
Ledda, A. [2 ]
Montefusco, V. [2 ]
Omede, P. [1 ]
Galli, M. [2 ]
Cavo, M. [2 ]
Palumbo, A. [1 ,3 ,4 ]
Musto, P. [2 ]
Boccadoro, M. [1 ]
机构：
[1] Univ Torino, Div Hematol, Myeloma Unit, Turin, Italy
[2] Italian Multiple Myeloma Network, Gimema, Italy
[3] Takeda Pharmaceut Co Employee, Turin, Italy
[4] Takeda Pharmaceut Co, Zurigo, Switzerland
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S410
引用
收藏
页码：143 / 144
页数：2
相关论文
共 50 条
  • [21] A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group
    Gregersen, Henrik
    Peceliunas, Valdas
    Remes, Kari
    Schjesvold, Fredrik H.
    Abildgaard, Niels
    Nahi, Hareth
    Andersen, Niels Frost
    Vangsted, Annette Juul
    Klausen, Tobias Wirenfeldt
    Helleberg, Carsten
    Carlson, Kristina
    Frolund, Ulf Christian
    Axelsson, Per
    Stromberg, Olga
    Blimark, Cecilie Hveding
    Linder, Olle
    Tsykunova, Galina
    Waage, Anders
    Hansson, Markus
    Gulbrandsen, Nina
    BLOOD, 2019, 134
  • [22] CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Catalano, L.
    Nappi, D.
    Musuraca, G.
    Lucchesi, A.
    Pareto, A. E.
    Di Perna, M.
    Ferrara, K.
    Ronconi, S.
    Ceccolini, M.
    Cangini, D.
    Giannini, M. B.
    Di Battista, V.
    Simonetti, G.
    Ferrari, A.
    Bochicchio, M. T.
    di Rora, A. Ghelli Luserna
    Ghetti, M.
    Napolitano, R.
    Fontana, M. C.
    Padella, A.
    Pane, F.
    Martinelli, G.
    HAEMATOLOGICA, 2020, 105 : S104 - S104
  • [23] Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma
    Cerchione, Claudio
    Ferrara, Katia
    Peluso, Ilaria
    Di Perna, Maria
    Nappi, Davide
    Pareto, Anna Emanuele
    Pane, Fabrizio
    Catalano, Lucio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S255 - S255
  • [24] Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma
    Cerchione, Claudio
    Nappi, Davide
    Pareto, Anna Emanuele
    Pane, Fabrizio
    Catalano, Lucio
    Martinelli, Giovanni
    BLOOD, 2021, 138
  • [25] CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Ferrara, K.
    Peluso, I.
    Di Perna, M.
    Zacheo, I.
    Nappi, D.
    Pareto, A. E.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : S85 - S85
  • [26] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
    Tan, Carlyn
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Patel, Dhwani
    Maclachlan, Kylee H.
    Lahoud, Oscar B.
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Korde, Neha
    Usmani, Saad
    BLOOD, 2022, 140 : 1817 - 1819
  • [27] Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma.
    Cerchione, Claudio
    Martinelli, Giovanni
    Nappi, Davide
    Pareto, Anna Emanuele
    Di Perna, Maria
    Ferrara, Katia
    Pane, Fabrizio
    Catalano, Lucio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Maclachlan, Kylee H.
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander
    Usmani, Saad Z.
    BLOOD, 2023, 142
  • [29] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [30] Carfilzomib-lenalidomide-dexamethasone Vs. lenalidomide-dexamethasone in non-frail transplant-ineligible patients with newly diagnosed multiple myeloma: the EMN20 trial
    D'Agostino, Mattia
    Antonioli, Elisabetta
    Gamberi, Barbara
    Bruno, Benedetto
    Derudas, Daniele
    Tosi, Patrizia
    Fazio, Francesca
    Carlo-Stella, Carmelo
    Ronconi, Sonia
    Corradini, Paolo
    Ballanti, Stelvio
    Cellini, Claudia
    Falcone, Antonietta Pia
    Bringhen, Sara
    Offidani, Massimo
    Rambaldi, Alessandro
    Rota-Scalabrini, Delia
    Agazzi, Alberto
    Casaluci, Gloria Margiotta
    Pietrantuono, Giuseppe
    Patriarca, Francesca
    Larocca, Alessandra
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S94 - S95
12345